DE60033679D1 - Herstellung von rekombinanten adenoviren und von adenovirus-genbanken - Google Patents

Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Info

Publication number
DE60033679D1
DE60033679D1 DE60033679T DE60033679T DE60033679D1 DE 60033679 D1 DE60033679 D1 DE 60033679D1 DE 60033679 T DE60033679 T DE 60033679T DE 60033679 T DE60033679 T DE 60033679T DE 60033679 D1 DE60033679 D1 DE 60033679D1
Authority
DE
Germany
Prior art keywords
adenovirus
adenovires
genban
recombinant
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033679T
Other languages
English (en)
Other versions
DE60033679T2 (de
Inventor
Jean-Jacques Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE60033679D1 publication Critical patent/DE60033679D1/de
Publication of DE60033679T2 publication Critical patent/DE60033679T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60033679T 1999-10-07 2000-10-05 Herstellung von rekombinanten adenoviren und von adenovirus-genbanken Expired - Lifetime DE60033679T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9912521A FR2799472B1 (fr) 1999-10-07 1999-10-07 Preparation d'adenovirus recombinants et de banques adenovirales
FR9912521 1999-10-07
US16835699P 1999-12-01 1999-12-01
PCT/FR2000/002774 WO2001025463A1 (fr) 1999-10-07 2000-10-05 Preparation d'adenovirus recombinants et de banques adenovirales
US168356P 2009-04-10

Publications (2)

Publication Number Publication Date
DE60033679D1 true DE60033679D1 (de) 2007-04-12
DE60033679T2 DE60033679T2 (de) 2007-11-15

Family

ID=26235132

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033679T Expired - Lifetime DE60033679T2 (de) 1999-10-07 2000-10-05 Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Country Status (22)

Country Link
US (1) US8263395B2 (de)
EP (1) EP1224310B1 (de)
JP (1) JP5260815B2 (de)
KR (1) KR100928105B1 (de)
CN (1) CN1384885B (de)
AT (1) ATE355385T1 (de)
AU (1) AU785431B2 (de)
BR (1) BR0014489B1 (de)
CA (1) CA2383225C (de)
CZ (1) CZ302282B6 (de)
DE (1) DE60033679T2 (de)
DK (1) DK1224310T3 (de)
FR (1) FR2799472B1 (de)
HK (1) HK1050211B (de)
HU (1) HU228933B1 (de)
IL (2) IL148493A0 (de)
MX (1) MXPA02003247A (de)
NO (1) NO330916B1 (de)
NZ (1) NZ518763A (de)
PL (1) PL210590B1 (de)
WO (1) WO2001025463A1 (de)
ZA (1) ZA200202481B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234980A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
EP2471909A1 (de) * 2010-12-30 2012-07-04 SIRION BIOTECH GmbH Nukleinsäuremoleküle zur Herstellung adenoviraler Vektoren
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) * 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (de) 1992-12-03 1995-09-27 Genzyme Corporation GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2705363B1 (fr) 1993-05-13 1995-08-11 Clecim Sa Procédé de fusion de ferraille dans un four électrique et installation pour la mise en Óoeuvre du procédé.
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2724945B1 (fr) * 1994-09-27 1996-12-27 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
AU724922B2 (en) * 1995-06-07 2000-10-05 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
FR2755975B1 (fr) 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
US5846812A (en) * 1996-11-22 1998-12-08 Pioneer Hi-Bred International, Inc. Zearalenone detoxification compositions and methods
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6844270B2 (en) * 2000-11-26 2005-01-18 Shipley Company, L.L.C. Polymers and photoresist compositions for short wavelength imaging
SE523617C2 (sv) * 2001-10-01 2004-05-04 Sandvik Ab Skär för spånavskiljande bearbetning försedd med spånbrytande geometri
JP4308485B2 (ja) * 2002-07-08 2009-08-05 パナソニック株式会社 容量素子の製造方法
US6856551B2 (en) * 2003-02-06 2005-02-15 Sandisk Corporation System and method for programming cells in non-volatile integrated memory devices

Also Published As

Publication number Publication date
AU785431B2 (en) 2007-05-31
DE60033679T2 (de) 2007-11-15
HU228933B1 (en) 2013-06-28
BR0014489A (pt) 2002-06-04
US20090149349A1 (en) 2009-06-11
KR100928105B1 (ko) 2009-11-24
CA2383225A1 (fr) 2001-04-12
JP5260815B2 (ja) 2013-08-14
KR20020057969A (ko) 2002-07-12
IL148493A (en) 2010-04-15
CN1384885B (zh) 2011-06-22
BR0014489B1 (pt) 2013-05-21
AU7794700A (en) 2001-05-10
US8263395B2 (en) 2012-09-11
EP1224310A1 (de) 2002-07-24
WO2001025463A1 (fr) 2001-04-12
FR2799472A1 (fr) 2001-04-13
NZ518763A (en) 2005-01-28
CZ20021215A3 (cs) 2002-08-14
HK1050211B (zh) 2008-01-25
ZA200202481B (en) 2003-09-23
ATE355385T1 (de) 2006-03-15
IL148493A0 (en) 2002-09-12
CN1384885A (zh) 2002-12-11
FR2799472B1 (fr) 2004-07-16
PL354099A1 (en) 2003-12-29
JP2003512823A (ja) 2003-04-08
HUP0203801A2 (hu) 2003-03-28
CZ302282B6 (cs) 2011-02-02
DK1224310T3 (da) 2007-07-02
MXPA02003247A (es) 2002-09-30
HUP0203801A3 (en) 2005-01-28
CA2383225C (fr) 2011-12-13
NO330916B1 (no) 2011-08-15
NO20021634L (no) 2002-06-04
HK1050211A1 (en) 2003-06-13
PL210590B1 (pl) 2012-02-29
EP1224310B1 (de) 2007-02-28
NO20021634D0 (no) 2002-04-05

Similar Documents

Publication Publication Date Title
ATE310829T1 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
EP1180932A4 (de) Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
NO950939D0 (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
BR9815419A (pt) genes desaturase e uso dos mesmos
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
DK0843731T3 (da) Adenovirusvektorer til genterapi
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
FR2778670B1 (fr) Methodes et compositions pour la production de particules virales
GB2379446A (en) Cells,culture methods and their uses
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells
EP1593742A3 (de) Rekombinante adenovirale Vektoren, die chimäre Fiberproteine exprimieren, für die zellspezifische Infektion
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
Ezzell Stem cell showstopper?
AU2000265672A1 (en) Somatic cloning gene transfer for the production of recombinant proteins, cells and organs
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
Moses It takes three years to build a Village.
EP1607483A4 (de) Mit einem virusvektor und einem menschlichen tumorsuppressorgen konstruierte rekombinante und ihre verwendung
DE69939825D1 (de) Genetische transduktion von hämatopoietische vorläuferzellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition